• Diminished severity and frequency of infectious complications of chronic granulomatous disease.
• Slow disease progression in severe, malignant osteopetrosis.

Contraindicated in:

• Hypersensitivity to interferon gamma, Escherichia coli–derived products, mannitol, or polysorbate.

Use Cautiously in:

• cardiovascular disease
• Bone marrow depression
• Pregnancy, lactation, or children <1 yr (safety not established).

GI: nausea, vomiting, abdominal pain.

Derm: rash.

Hemat: neutropenia, thrombocytopenia.

Local: edema or tenderness at injection site.

MS: arthralgia, myalgia, back pain.

Neuro: gait disturbances , headache, decreased mental status, dizziness.

Misc: chills, fever.

Drug-Drug:

• May have additive bone marrow–depressing effects with antineoplastics or radiation therapy.

• Injection: 100 mcg (3 million units)/vial;

Body Surface Area >0.5 m²

• SC (Children): 50 mcg/m² (1 million units/m²) 3 times weekly.

Body Surface Area 0.5 m²

• SC (Children >1 yr): 1.5 mcg/kg 3 times weekly.

Actimmune

• A protein produced by recombinant DNA technology that is capable of activating phagocytes, enhancing their ability to kill pathogens, including:
  • Staphylococcus aureus,
  • Toxoplasma gondii,
  • Leishmania donovani,
  • Listeria monocytogenes,
  • Mycobacterium avium intracellulare.
• Interferon gamma has antiproliferative effects superior to interferon alpha and beta.

• Decreased incidence and severity of infection in patients with chronic granulomatous disease.
• Slowed disease progression of severe, malignant osteopetrosis.

Therapeutic Classification: immune modifiers

Pharmacologic Classification: interferons

Absorption: Well absorbed after SUBQ administration.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-life: 5.9 hr.

(blood levels)

• Home Care Issues: Instruct patient or family on proper technique for administering injection and care and disposal of equipment. Provide a puncture-proof container for disposal of needles.
  • Advise patient of the need for contraception throughout therapy.

in-ter-FEER-on

NDC Code^*

• 17089- Guna spa
  • 17089-378- GUNA-INF GAMMA
    • 17089-378-18- 1 BOTTLE, DROPPER in 1 BOX (17089-378-18) > 30 mL in 1 BOTTLE, DROPPER

• 75987- Horizon Therapeutics USA, Inc.
  • 75987-111- ACTIMMUNE
    • 75987-111-11- 12 VIAL, SINGLE-USE in 1 CARTON (75987-111-11) >.5 mL in 1 VIAL, SINGLE-USE (75987-111-10)